Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Kymera Therapeutics Stock Up 5.6 %
KYMR stock opened at $49.03 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $50.69. The firm has a 50 day moving average of $44.93 and a two-hundred day moving average of $38.97. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -19.53 and a beta of 2.22.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. Kymera Therapeutics’s revenue was up 55.2% compared to the same quarter last year. During the same period last year, the business posted ($0.67) EPS. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.87 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on Kymera Therapeutics
Institutional Trading of Kymera Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after buying an additional 996,300 shares during the last quarter. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Norges Bank acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at $12,834,000. Artal Group S.A. lifted its position in Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after purchasing an additional 496,400 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Kymera Therapeutics by 229.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock worth $17,177,000 after buying an additional 469,947 shares in the last quarter.
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Why Are These Companies Considered Blue Chips?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.